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Abstract
Background The term ‘metabolome’ was introduced to the
scientific literature in September 1998.
Aim and key scientific concepts of the review To mark its
18-year-old ‘coming of age’, two of the co-authors of that
paper review the genesis of metabolomics, whence it has
come and where it may be going.
Keywords Metabolome  Functional genomics  Systems
biology  Precision medicine
1 Introduction
The great advances in biology leading up to the discovery of
the structure of DNA and the definition of the genetic code
(Cobb 2015; Judson 1979), and the tremendous strides made
since then, have been mainly pioneered by molecular genetic
studies on model organisms such as Escherichia coli and
yeasts (Saccharomyces cerevisiae and Schizosaccha-
romyces pombe) (Castrillo and Oliver 2004). The genius of
molecular genetics lay in the design of experiments whereby
fundamental theories of the workings of living cells at the
molecular level could be rigorously tested by performing
experiments that had a qualitative read-out (either the cells
grew or they did not; either colonies were blue or they were
not). This was set to change when the first chromosome
sequence to be completed (that of S. cerevisiae chromosome
III; Oliver et al. 1992) revealed that only about 20 % of the
protein-encoding genes had previously been discovered by
classical genetics augmented by recombinant DNA tech-
nology. It was immediately evident that the normal course of
genetic research, which proceeds from mutant phenotypes to
the definition of the corresponding genotype, had to be
reversed. Since DNA sequencing would define all the genes,
in the future we would need to move from gene to function,
rather than from function to gene (Kell and Oliver 2004)
(Fig. 1). This functional analysis would need to be con-
ducted using techniques that were every bit as comprehen-
sive as genome sequencing, and so the different levels of
’omic analysis were conceived (Oliver 1996).
Transcriptomics (the analysis of the complete comple-
ment of (m)RNA molecules in a cell, tissue, or organ) had the
twin advantages of being most closely related to genomics
and that it could be pursued using similar techniques—either
by hybridisation of complementary nucleic acid strands or
cDNA sequencing. Like the other functional’omes the
transcriptome is context-dependent—it changes with the
changing physiological, pathological, or developmental
state of the cell. For yeast cells, the relationship between the
genome and transcriptome is approximately one-to-one;
introns and, therefore, differential splicing of mRNAs are
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rare in yeast (Hirschman et al. 2006; Stajich et al. 2007).
Proteomics (Wilkins et al. 1996) (the analysis of the com-
plete complement of protein molecules) was also context-
dependent, but the relationship (even in yeast) was one-to-
many due to post-translational processing and modification
of the primary polypeptides generated by protein synthesis.
These were the ‘‘natural’’ ’omes that followed from the
maxim that ‘‘DNA makes RNA makes protein’’ (and then
apparently stops), a maxim that signalled still that ‘molecular
biology’ for most people meant ‘macromolecular biology’.
Despite its obvious importance in biotechnology (e.g.
Bu’lock 1961; Dikicioglu et al. 2013; Nielsen and Keasling
2016), metabolism was seen at that time as something of a
Cinderella subject (Griffin 2006), and only a few had pio-
neered such analyses.
2 A little pre-history
Although it was not called metabolomics, a few early
workers had developed interests in using more or less
comprehensive metabolic profiling systems to understand
complex biological systems. Thus Williams, an early
advocate of what we would now call ‘precision medicine’
(Williams 1956), recognised the potential utility of such
methods, and the Hornings and their colleagues were at the
forefront of instrumental implementations (Dalgliesh et al.
1966; Horning and Horning 1971). DBK carried out his D.
Phil (1975–1978) in the laboratory of F. R. (‘Bob’)
Whatley, whose colleague Bill Greenaway was explicitly
developing GC–MS methods for the analysis of pathogenic
fungi and the mode of action of fungicides. Partly because
of the help of an anonymous donor with an interest in the
health-giving properties of propolis (Greenaway et al.
1991), the pressure to publish then was not so intense, and
this kind of work only appeared rather subsequently (Grant
et al. 1988). (It was also based on a naı¨ve interpretation of
the ‘crossover theorem’ (Chance and Williams 1955), and
lacked the theoretical foundations that metabolic control
analysis and systems biology—see below—could provide.)
At the time, much of it involved improving the repro-
ducibility, and the production (on a 5Mbyte ‘‘Winchester’’
hard disk the size of a bicycle wheel) of a database of mass
spectra. Plus c¸a change, one might say!
3 The metabolome
Meanwhile, and while proteomics appeared daunting, per-
forming functional analysis at the level of the metabolites
appeared far more tractable since we calculated (wrongly, as
it turned out: Jewison et al. 2012) that there were only
600–700 metabolites in the yeast cell—about an order of
magnitude less than the number of protein-encoding genes
(Goffeau et al. 1996). The complete complement of
metabolites was also context-dependent, but there was no
direct link to the genome since many genes may determine
the synthesis and turnover of a single metabolite. Another
major difficulty compared with the transcriptome and pro-
teome was the recognition that the physical properties of
metabolites were much more widely varied making the
metabolites much more differentially extractable, and also
that many were quite labile. On the other hand, the metabolic
profile was directly and immediately linked to function, and
potentially comprehensive methods of analysis (especially
mass spectrometry and nuclear magnetic resonance) were
available. Metabolic control analysis (MCA) (Fell
1992, 1996; Heinrich and Rapoport 1974; Heinrich and
Schuster 1996; Kacser and Burns 1973; Kell et al. 1989; Kell
and Westerhoff 1986), a precursor of modern metabolic
network biology (Palsson 2006), had long explained why
changes in the levels of individual genes or transcripts had
relatively little effect on metabolic fluxes, but that they could
necessarily—and for precisely the same reasons—have
potentially very large effects on metabolite concentrations.
Thus, we reasoned, also given that microbes tend to favour
growth rate over growth yield (Westerhoff et al. 1983), that
in order to maintain the fluxes through the metabolic net-
works at a relatively constant level, microbial cells would
have to vary the concentrations of their constituent
metabolites over a wide range—thus the concept, and the
term, ‘metabolome’ was born (Oliver et al. 1998).
The initial test of the concept was pioneered in a collabo-
rative effort between our laboratories (then in Manchester and
Aberystwyth) and those of Kevin Brindle (in Cambridge) and
Fig. 1 The ‘forward’ and ‘reverse’ strategies that have been used to
link genes and phenotypes. Classically, one would start with a
function and seek gene(s) responsible. As it became clearer that most
genes were phenotypically silent, it emerged from the systematic
genome sequencing programs that only a small fraction of genes had
been discovered in this way. The systematic genome sequencing
programs also served to change this completely, as once one ‘had’ the
genes it was necessary to discover their function. A similar story can
be written for drug discovery (Kell 2013)
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Hans Westerhoff/Karel van Dam (in Amsterdam). The idea
was that we should be able to elucidate the role of genes of
unknown function by comparing the metabolomes of their
deletion mutants with those of the deletion mutants of genes of
known function. This concept, often called ‘‘guilt by associa-
tion’’ (Oliver 2000), and a standard strategy in the older ‘op-
erational fingerprinting’ (Meuzelaar et al. 1982) and the newer
machine learning (Goodacre et al. 1998), was to become a
prevalent one in functional genomics. In this specific example,
the use of metabolomics to reveal similarities between yeast
mutants was termed FANCY, for Functional ANalysis by Co-
responses in Yeast, by Bas Teusink (Teusink et al. 1998)—an
acronym which, for better or worse, never caught on. For all
that, the concept was robustly validated by the association of
the metabolomes of pfk26 and pfk27 deletants, and also those
of a number of nuclear petite mutants (Raamsdonk et al. 2001;
Cornish-Bowden and Ca´rdenas 2001). What was remarkable
about this proof-of-principle study was that it worked at all,
given the small number of metabolites identified in the NMR
analyses. The notion that it was only necessary to monitor the
most connected metabolites was tested in Kevin Brindle’s lab,
using classical biochemical analyses, but this only served to
emphasise the importance of using just one analytical tech-
nique to quantify all metabolites. The discriminatory power of
just a limited metabolome inspired DBK to suggest monitoring
the metabolites excreted into the growth medium—the meta-
bolic ‘footprint’ or exometabolome (Allen et al. 2003, 2004;
Kaderbhai et al. 2003; Kell et al. 2005), of which more later.
We also recognised that Direct Injection Mass Spectrometry
(DIMS) could be used to speciate intact bacterial cells (Vai-
dyanathan et al. 2001) and other substances (Goodacre et al.
2002), and this DIMS approach has recently been exploited to
great effect by Uwe Sauer and colleagues (Link et al. 2015) to
analyse the endometabolome by directly injecting living cells
into a high-resolution mass spectrometer.
However, the most important outcome of this study was
that metabolomics was rapidly embraced across the biolog-
ical research community, and especially by plant biologists
(Fiehn 2002; Fiehn et al. 2000; Jenkins et al. 2004) despite
(or perhaps because of; Quanbeck et al. 2012) the fact that
higher plants are considered to have the largest and most
complex metabolomes in the living world. (However, we
note as a caveat that most microbes have still not been
brought into laboratory culture and their many secondary
metabolites decrypted (Kell et al. 2015a; Lewis et al. 2010)).
4 The previous 18 years
In a 2004 review (Kell 2004), one of us used the methods
of text mining to analyse the areas in which metabolomics
research was then most focused, identifying three main
clusters: technological developments, the integration of
metabolomics with other ’omics (Castrillo et al. 2007), and
its use in predicting higher order properties such as disease.
Shortly afterwards the Metabolomics Society and this
journal were founded, with the annual meetings now
attracting almost 1000 participants. The annual numbers of
papers with the term metabolom* in their title or abstract
continue to rise, and in 2015 amounted, at Web of
Knowledge, to 3130 (in a total exceeding 18,000).
Consequently, the space available does not permit us to be
even faintly comprehensive about the development of
metabolomics—the papers in this journal provide an excel-
lent starting point—but the massive improvement in mass
spectrometric and chromatographic methods is clearly a
huge driver (Dettmer et al. 2007; Makarov et al. 2006)) and
has been so for us (e.g. (Begley et al. 2009; Dunn et al.
2011, 2015; Goodacre et al. 2004; O’Hagan et al. 2005;
Zelena et al. 2009), as are improvements in mass precision
and metabolite identifiability (Brown et al. 2009; Dunn et al.
2013; Kind and Fiehn 2007; Weber et al. 2011). We have also
found the development of metabolic footprinting (Allen et al.
2003, 2004; Kell et al. 2005) (‘exometabolomics’) to be of
value, and like many others have used both untargeted
metabolomics and the related metabolic profiling (Goodacre
et al. 2004) to discover new disease biomarkers (e.g. (Dunn
et al. 2007; Kenny et al. 2005, 2010)).
The importance of metabolomics databases (Haug et al.
2013; Skogerson et al. 2011; Wishart et al. 2013; Zhu et al.
2013) and the need to make metabolomics data publically
available (Rocca-Serra et al. 2016; Salek et al. 2015)
cannot be stressed too highly.
An important trend is the use of 13C labelling for mea-
suring fluxes (Zamboni et al. 2009), as well as the inte-
gration of experimental metabolomics with the genome-
wide metabolic networks that are becoming available
(Herrga˚rd et al. 2008; Swainston et al. 2016; Thiele et al.
2013). Equivalently, and sadly, an important non-trend is
any major improvement in the proper use of statistical and
related (machine learning) methods in biological (Ioannidis
2005) and especially metabolomics (Broadhurst and Kell
2006) studies.
5 Quo vadis? How will the full potential
of metabolomics be revealed?
‘‘It has been said that we always overestimate what
we can do in two years and underestimate what we
can do in twenty.’’
P. Ball & L. Garwin (Ball and Garwin 1992)
Given the above caveat, we do not seek to be overly
predictive, but some trends are obvious. The improvement
in sample scale (with (Dunn et al. 2011, 2015) or
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potentially without (Lewis et al. 2016) the need for drift
correction) is clearly one, and this will be aided by the
continuing development of inter-laboratory comparisons
(Abate-Pella et al. 2015) and standards for data, data
analysis, and interoperability and data integration (Good-
acre et al. 2007; Grapov et al. 2015; Salek et al.
2013, 2015; Sansone et al. 2007). Such things will assist
greatly in the development of personalised medicine and its
integration with wearable technologies. As well as the
anticipated trends in sensitivity, moving towards the nec-
essary single-cell analyses, it is clear that many more
metabolites remain to be discovered, even in simple hosts
(Carbonell et al. 2013, 2014) (probably as a result of
enzyme promiscuity Currin et al. 2015; Jeffryes et al.
2015). Such analyses are greatly aided by the use of proper
descriptors of small molecule structures, such as SMILES
(Weininger 1988) and InChI (Coles et al. 2005; Heller et al.
2013; Spjuth et al. 2013), that allow cheminformatic rea-
soning about properties such as drug-metabolite similari-
ties (Dobson et al. 2009b; O’Hagan and Kell 2015b,
O’Hagan and Kell 2016; O’Hagan et al. 2015).
Another trend will be further automation of instrument
tuning (Bradbury et al. 2015), non-invasive methods (Rat-
tray et al. 2014), and an increased portability of instrumen-
tation such that it may even be used in the field (as is now the
case for genomics (Ashton et al. 2015; Kilianski et al. 2015)
and biometrics). This is clearly assisted by ‘ambient mass
spectrometry’ (Cooks et al. 2006), and the impressive
‘iKnife’ (Alexander et al. 2016; Balog et al. 2013) pioneering
of such measurements in the operating theatre. This kind of
development will be especially important in terms of envi-
ronmental metabolomics (Bundy et al. 2009) and the ‘ex-
posome’ (the integrated load of xenobiotics that an
individual has accumulated in his/her lifetime) (Athersuch
and Keun 2015; Rappaport et al. 2014). The extensive data
that will be generated will be harvested via the ‘Internet of
Things’ (Ellis et al. 2015), scientific reasoning will be further
automated (King et al. 2004, 2009; Williams et al. 2015), and
in an era where the methods of ‘artificial intelligence’ are
starting to show human-level abilities, at least in restricted
domains (Koza 2010; Mnih et al. 2015; Silver et al. 2016), we
shall be wise to exploit such methods.
At least as judged by their appearance in the literature,
some enzymes in a given organism are much more greatly
studied than are others, a phenomenon referred to as ‘pub-
lication asymmetry’ (Ce´sar-Razquin et al. 2015). As asses-
sed in that paper (Ce´sar-Razquin et al. 2015), solute carriers
(SLCs (Hediger et al. 2004)) or transporters are the most
neglected group of genes in the human genome. Our own
analyses also point up their major importance in flux control
(Walter et al. 1987), drug transport (Dobson et al. 2009a;
Dobson and Kell 2008; Kell 2013, 2015a, 2015b, 2016; Kell
et al. 2013, 2011; Kell and Oliver 2014; Lanthaler et al. 2011;
Mendes et al. 2015; O’Hagan and Kell 2015a) and biotech-
nology (Kell et al. 2015b). Thus we consider that, although
challenging, compartment-based metabolomics, where such
transporters are necessarily involved, is likely to become a
substantial field of itself. Indeed, our improved understand-
ing of a special compartment called the microbiome shows
that not all of the genes and metabolites involved in sup-
posedly non-communicable diseases even arise from the host
(Honda and Littman 2016; Potgieter et al. 2015; Wang et al.
2011; Wikoff et al. 2009).
Biological studies will be much aided by the ability to
manipulate genomes at will. Henrik Kacser, as a major part
of his motivation for developing MCA in the first place,
had long ago explained why much more sensitive analyses
are possible with haploids than with diploids (Kacser and
Burns 1981). Thus, a particularly nice example was given
by the work of Superti-Furga and colleagues (Winter et al.
2014) on a near-haploid cell line showing that at least
99.5 % of the uptake of the drug sepantronium bromide
proceeded through a specific transporter, and thus that any
transbilayer flux was negligible.
The original paper (Oliver et al. 1998) concluded ‘‘many
of these techniques are sufficiently general that, once they
have been tried and tested in the experimentally
tractable yeast system, they should be directly applicable to
the study of the functional genomics of higher organisms’’.
Certainly this has been borne out, and overall, then,
metabolomics has had a very healthy childhood and ado-
lescence. Perhaps now the exposome, and even more
comprehensive studies, will usher in the (for us much-
vaunted (Kell 2004, 2006; Kell et al. 2005) but largely
awaited) integration of metabolomics and systems biology.
If it does, it will have been well worth the wait.
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